Thoughts on liver transplantation for hepatocellular carcinoma in the era of immunotherapy
10.12464/j.issn.1674-7445.2026141
- VernacularTitle:免疫治疗时代关于肝癌肝移植的思考
- Author:
Shuxian SONG
1
;
Zhao LI
2
Author Information
1. Department of Hepatobiliary Surgery, Peking University People's Hospital, Organ Transplantation Institute of Peking University, Liver Cancer Diagnosis and Treatment Research Center of Peking University, Beijing 100044, China;.
2. Department of Hepatobiliary Surgery, Peking University People's Hospital, Organ Transplantation Institute of Peking University, Liver Cancer Diagnosis and Treatment Research Center of Peking University, Beijing 100044, China.
- Publication Type:TransplantationForefront
- Keywords:
Hepatocellular carcinoma;
Liver transplantation;
Immune checkpoint inhibitor;
Milan criteria;
Downstaging therapy;
Bridging therapy;
Rejection;
Immune induction
- From:
Organ Transplantation
2026;17(6):926-935
- CountryChina
- Language:Chinese
-
Abstract:
The emergence and development of immune checkpoint inhibitors have ushered in the era of immunotherapy for hepatocellular carcinoma (HCC). The emerging treatment methods not only bring long-term survival hope to patients with advanced HCC, but also profoundly influence the clinical practice of liver transplantation for HCC. However, the current clinical evidence regarding the use of immunotherapy during the perioperative period of liver transplantation for HCC patients is still limited, and the potential clinical benefits coexist with the risk of rejection. How to establish a predictable and manageable management system in key aspects, such as the selection of beneficiaries, adjustment of immunosuppressive regimens and early warning of rejection, is a core issue that urgently needs to be addressed. This article combines existing research and the author's clinical experience to focus on liver transplantation for HCC under the background of immunotherapy, analyzes the current key problems, aiming to provide references for clinical practice and promote the conduct of high-quality clinical research.
